These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8809171)

  • 1. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
    Daines RA; Chambers PA; Foley JJ; Griswold DE; Kingsbury WD; Martin LD; Schmidt DB; Sham KK; Sarau HM
    J Med Chem; 1996 Sep; 39(19):3837-41. PubMed ID: 8809171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB 209247, a high affinity LTB4 receptor antagonist demonstrating potent antiinflammatory activity.
    Sarau HM; Foley JJ; Schmidt DB; Tzimas MN; Martin LD; Daines RA; Chambers PA; Kingsbury WD; Griswold DE
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():275-7. PubMed ID: 7732852
    [No Abstract]   [Full Text] [Related]  

  • 3. (E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
    Daines RA; Chambers PA; Eggleston DS; Foley JJ; Griswold DE; Haltiwanger RC; Jakas DR; Kingsbury WD; Martin LD; Pendrak I
    J Med Chem; 1994 Sep; 37(20):3327-36. PubMed ID: 7932560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.
    Sarau HM; Foley JJ; Schmidt DB; Martin LD; Webb EF; Tzimas MN; Breton JJ; Chabot-Fletcher M; Underwood DC; Hay DW; Kingsbury WD; Chambers PA; Pendrak I; Jakas DR; Sathe GM; Van Horn S; Daines RA; Griswold DE
    Prostaglandins Leukot Essent Fatty Acids; 1999 Jul; 61(1):55-64. PubMed ID: 10477044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.
    Daines RA; Chambers PA; Pendrak I; Jakas DR; Sarau HM; Foley JJ; Schmidt DB; Kingsbury WD
    J Med Chem; 1993 Oct; 36(22):3321-32. PubMed ID: 8230122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain.
    Chan WK; Huang FC; Morrissette MM; Warus JD; Moriarty KJ; Galemmo RA; Dankulich WD; Poli G; Sutherland CA
    J Med Chem; 1996 Sep; 39(19):3756-68. PubMed ID: 8809164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity.
    Kenny JR; Maggs JL; Tettey JN; Harrell AW; Parker SG; Clarke SE; Park BK
    Drug Metab Dispos; 2005 Feb; 33(2):271-81. PubMed ID: 15523047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The leukotriene B4 receptor agonist/antagonist activities of SC-45694 in human neutrophils.
    Tsai BS; Keith RH; Villani-Price D; Haack RA; Djuric SW
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1493-8. PubMed ID: 8138959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
    Daines RA; Chambers PA; Pendrak I; Jakas DR; Sarau HM; Foley JJ; Schmidt DB; Griswold DE; Martin LD; Tzimas MN
    J Med Chem; 1993 Sep; 36(18):2703-5. PubMed ID: 8410983
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel series of [2-[methyl(2-phenethyl)amino]-2-oxoethyl] benzene-containing leukotriene B4 antagonists: initial structure-activity relationships.
    Huang FC; Chan WK; Moriarty KJ; Poli G; Morrissette MM; Galemmo RA; Warus JD; Dankulich WP; Sutherland CA
    J Med Chem; 1996 Sep; 39(19):3748-55. PubMed ID: 8809163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
    Showell HJ; Pettipher ER; Cheng JB; Breslow R; Conklyn MJ; Farrell CA; Hingorani GP; Salter ED; Hackman BC; Wimberly DJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):176-84. PubMed ID: 7714764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
    Rao TS; Yu SS; Djuric SW; Isakson PC
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):213-28. PubMed ID: 7812673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.
    Kingsbury WD; Pendrak I; Leber JD; Boehm JC; Mallet B; Sarau HM; Foley JJ; Schmidt DB; Daines RA
    J Med Chem; 1993 Oct; 36(22):3308-20. PubMed ID: 8230121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.
    Birke FW; Meade CJ; Anderskewitz R; Speck GA; Jennewein HM
    J Pharmacol Exp Ther; 2001 Apr; 297(1):458-66. PubMed ID: 11259574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity.
    Nakayama Y; Senokuchi K; Sakaki K; Kato M; Maruyama T; Miyazaki T; Ito H; Nakai H; Kawamura M
    Bioorg Med Chem; 1997 May; 5(5):971-85. PubMed ID: 9208106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.
    Greenspan PD; Fujimoto RA; Marshall PJ; Raychaudhuri A; Lipson KE; Zhou H; Doti RA; Coppa DE; Zhu L; Pelletier R; Uziel-Fusi S; Jackson RH; Chin MH; Kotyuk BL; Fitt JJ
    J Med Chem; 1999 Jan; 42(1):164-72. PubMed ID: 9888841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of 2- and 4-(2-alkylcarbamoyl-1-methylvinyl)-7-alkyloxybenzo[b]furans having potent antagonistic activity against human leukotriene B4 BLT1 and/or BLT2 receptors.
    Ando K; Tsuji E; Ando Y; Kunitomo J; Yamashita M; Ohta S; Nabe T; Kohno S; Yokomizo T; Shimizu T; Ohishi Y
    Org Biomol Chem; 2004 Dec; 2(23):3427-31. PubMed ID: 15565232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous leukotriene B4 (LTB4) inhibits human neutrophil generation of LTB4 from endogenous arachidonic acid during opsonized zymosan phagocytosis.
    Fiedler J; Wheelan P; Henson PM; Murphy RC
    J Pharmacol Exp Ther; 1998 Oct; 287(1):150-6. PubMed ID: 9765334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro.
    Showell HJ; Breslow R; Conklyn MJ; Hingorani GP; Koch K
    Br J Pharmacol; 1996 Mar; 117(6):1127-32. PubMed ID: 8882606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.